Phathom Pharmaceuticals Q3 EPS $(0.76) Beats $(0.89) Estimate
Portfolio Pulse from Benzinga Newsdesk
Phathom Pharmaceuticals reported Q3 losses of $(0.76) per share, beating the analyst consensus estimate of $(0.89) by 14.61%. This is a 42.42% increase over losses of $(1.32) per share from the same period last year.
November 09, 2023 | 1:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phathom Pharmaceuticals' Q3 losses were less than expected, indicating a positive financial performance.
Phathom Pharmaceuticals reported a smaller loss than expected for Q3, which is a positive sign for the company's financial health. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100